FEB 15, 2014
Glaucoma, Surgical Management
In this interview, Dr. Steven Vold summarizes current and future technologies for microinvasive glaucoma surgery (MIGS). Procedures under this MIGS category are generally defined by the use of ab interno microstent devices that improve aqueous outflow. These devices show significant potential for market growth as they prove effective and safe in patients with moderate glaucoma. Dr. Vold reviews both existing and new devices that bypass the trabecular meshwork (iStent, iStent Inject, and Hydrus), as well as those devices that target the suprachoroidal or subconjunctival space (iStent Supra, CyPass microstent, XEN gel stent, and InnFocus microshunt). As the designs, materials, and surgical techniques associated with these devices evolve, Dr. Vold believes MIGS offers the hope of improved outcomes, faster visual recovery, and greater safety than traditional filtering surgery.